Next Article in Journal
Mapping Magnetic Properties and Relaxation in Vanadium(IV) Complexes with Lanthanides by Electron Paramagnetic Resonance
Previous Article in Journal
Starch Components, Starch Properties and Appearance Quality of Opaque Kernels from Rice Mutants
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 24
10.3390/molecules24244581
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a New Class of Antistaphylococcal Agents: Synthesis and Biological Evaluation

by
Viktor Zvarych
1,
Maryna Stasevych
1,*,
Volodymyr Novikov
1,
Eduard Rusanov
2,
Mykhailo Vovk
2,
Piotr Szweda
3,
Katarzyna Grecka
3 and
Slawomir Milewski
3
1
Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv Politechnic National University, 13, 79013 Lviv, Ukraine
2
Department of Mechanism of Organic Reactions, Institute of Organic Chemistry of National Academy of Sciences of Ukraine, 02660 Kyiv, Ukraine
3
Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, 80-233 Gdańsk, Poland
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(24), 4581; https://doi.org/10.3390/molecules24244581
Submission received: 20 November 2019 / Revised: 6 December 2019 / Accepted: 12 December 2019 / Published: 13 December 2019
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
The development and spread of resistance of human pathogenic bacteria to the action of commonly used antibacterial drugs is one of the key problems in modern medicine. One of the especially dangerous and easily developing antibiotic resistant bacterial species is Staphylococcus aureus. Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38 have been developed as novel effective antistaphylococcal agents. These compounds have been obtained by sequential conversion of 1-amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1) and 1-amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (2) into the corresponding amides 5–21, followed by subsequent endo-cyclization under the influence of sodium nitrite in acetic acid. Evaluation of the antimicrobial activity of the synthesized compounds against selected species of Gram-positive and Gram-negative bacteria as well as pathogenic yeasts of the Candida genus has been carried out by the serial dilution method. It has been established that anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones exhibit selective antibacterial activity against Gram-positive bacteria. Eight, six and seven, out of seventeen compounds tested, effectively inhibited the growth of S. aureus ATCC 25923, S. aureus ATCC 29213 and S. epidermidis ATCC12228, respectively, at a concentration equal to 1 µg/mL or lower. The high antistaphylococcal potential of the most active compounds has been also confirmed against clinical isolates of S. aureus, including the MRSA strains. However, bacteria of the Staphylococcus genus have demonstrated apparent resistance to the novel compounds when grown as a biofilm. None of the four selected compounds 3234 and 36 at a concentration of 64 µg/mL (128 or 256 × MIC—against planktonic cells) has caused any decrease in the metabolic activity of the staphylococcal cells forming the biofilm. The kinetic time–kill assay revealed some important differences in the activity of these substances. Compound 33 is bacteriostatic, while the other three demonstrate bactericidal activity.

1. Introduction

The resistance of human pathogenic bacteria and yeasts to the well-known antibiotics and synthetic chemotherapeutics is becoming a major global health challenge [1,2,3]. Among the array of various antibiotic-resistant pathogenic bacteria, staphylococci belong to the most common and dangerous. They are able to produce a wide array of virulence factors and have evolved mechanisms of resistance to a plethora of antibiotics currently in use for human and animal therapies. As a consequence, bacteria of the Staphylococcus genus, particularly S. aureus, are responsible for a broad spectrum of difficult to treat diseases including skin and ocular infections, foodborne illness, pneumonia, meningitis, endocarditis, and osteomyelitis [4]. Over the past decades, this bacterium has become the main cause of bloodstream infections (BSI) in the world, with a mortality level of 20–40% [5]. Recent advances in the developments of antistaphylococcal agents are presented in works on search of new non-antibiotic agents: peptidoglycan hydrolases compounds of plant origin (plant extracts, essential oils and their components) [6,7,8,9], vaccines development [8], silver nanoparticles [10], bacteriocins [11], and bacteriophages [12]. Currently, the most reasonable approach for understanding the crucial cellular pathways by which unknown to date (or not used as antimicrobial agents) molecules affect pathogenic microorganisms at a molecular level seems to be transcriptome analysis. Recently, Chauhan and coworkers [13] successfully applied RNA sequencing for the determination of antistaphylococcal modes of action of novel discovered benzimidazole molecules. Comparative analysis of differentially expressed genes between control and treated S. aureus cells showed selective hits. Therefore, the search and development for new antibacterial agents effective against these pathogenic bacteria remain an urgent task of the present.
Derivatives of the 9,10-anthraquinone of both natural and synthetic origin are well known for their wide range of biological effects. Of particular interest, compounds with an antibacterial effect are known among them [14,15,16,17]. The 1,2,3-triazinone ring is an important biophore fragment for the creation of new promising antimicrobial agents based on the 9,10-anthraquinone platform. This pharmacophore is a structural component of many natural and synthetic biologically active compounds with various therapeutic effects [18,19]. The compounds with a sedative, diuretic, anesthetic, antiarthritic, antitumor, antibacterial, antifungal, antituberculosis, antiviral, antiinflammatory, antihistamine activity were found among 1,2,3-triazine derivatives connected with various carbo- and heterocyclic fragments [20,21,22,23].
It is known that diazotization of the corresponding ortho-amino amides with NaNO2 or t-BuONO under slightly acidic conditions is one of the most common methods for the formation of the 1,2,3-triazin-4-one ring [15]. Despite the widespread use of this method, condensed carbocyclic 1,2,3-triazin-4-one derivatives are known only for the benzene and naphthalene systems [24]. In the context of the above, herein we report a method for the synthesis of new triazine-containing anthraquinone structures and the study their antibacterial effect for identifying potential antimicrobial agents.

2. Results and Discussion

2.1. Chemistry

Continuing our research on the directed functionalization of the 9,10-anthraquinone system and the search for new biologically active substances [25,26,27,28,29,30], in the work presented herein we report an effective synthetic approach to a number of new condensed anthraquinone derivatives, namely anthra [1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38 (Scheme 1).
Commercially available 1-amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1) and 1-amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (2) were converted into the corresponding acid chlorides 3 and 4 by treatment with thionyl chloride in the presence of a catalytic amount of pyridine. The amides 5–21 were prepared from acid chlorides 3 and 4 and ammonia, cyclohexylamine and a variety of anilines (Scheme 1).
The target compounds 22–38 were synthesized via an intramolecular cyclization reaction of amides 5–21 with nitrous acid generated in situ in acetic acid at room temperature in 63–90% yields (Scheme 2). It should be noted that the use of t-BuONO as a diazotizing agent in the reactions at 20–65 °C proved to be ineffective and gave a low conversion of amides 5–21. Moreover, the presence of a bromine atom at the position 4 of the anthracenedione ring did not provide for a significant impact on the cyclization process.
The formation of amides 6,7,9,10,15,16,18 was confirmed by the presence of a broad singlet of proton of the NH group of the amide fragment in the range of 10.03–10.72 ppm in the 1H-NMR spectra. Also, the signal of protons of the NH2 group falls into the region of aromatic anthracenedione and benzene protons. The amide protons in N-cyclohexyl-substituted amides 8 and 17 resonated in the aromatic proton region of the quinoid ring.
The carbon atom signal of the carbonyl group of amide residue of 5–21 was observed within the range of 165.25–169.76 ppm in the 13C-NMR spectra. In the case of fluorine-containing amides 9,10,15,18, the characteristic doublet signals attributable to the C-F bond in the meta or para position of the benzene residue were presented in the range from 158.19 to 163.45 ppm with a coupling constant of J = 241.1 Hz.
The characteristic broad singlet signal of NH proton at 15.37 and 15.45 ppm was presented in the 1H-NMR spectra of anthratriazinones 22 and 31. In the 13C-NMR spectra of compounds 22,31, the signal of the carbon atom of the carbonyl group in the triazine ring was shifted by 16 ppm compared to the C=O group in the corresponding amides 5 and 14. Additionally, the structure of anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione 22 was confirmed by X-ray diffraction analysis (Figure 1).
In structure of compound 22 (Figure 2) the central tetracyclic system is strongly conjugated and planar (Rms deviation of fitted atoms 0.0399), while the atoms O2 and O3 deviate out of this plane for 0.200(3) and 0.154(3) Å respectively. In crystal molecules packed in columns directed along a crystallographic axis.
The shortest intermolecular distances between neighboring molecules in columns are 3.342 Å and 3.424 Å for C···N and C···C contacts correspondingly, thus π-π stacking in columns is observed. Solvate water molecules occupy volume between the columns and bonding together neighboring columns by the system of hydrogen bonds. The parameters of H-bonds in a crystal are shown in Table 1. The combination of π-π stacking in columns along axes a and 2D hydrogen bonds across b and c direction giving 3D net and densely packed crystal with density 1.59 g/cm3.

2.2. Biological Studies

2.2.1. Determination of MIC Values of Synthesized Agents against Reference Strains of Bacteria and Yeasts and Clinical Isolates of S. aureus

The outcomes of our investigation revealed that synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones exhibited selective antibacterial activity against staphylococci (Table 2). Eight, six and seven out of seventeenths compounds tested inhibited the growth of S. aureus ATCC 25923, S. aureus ATCC 29,213 and S. epidermidis respectively at a concentration equal to 1 µg/mL or lower. This level of activity is comparable to the activity of many antibacterial antibiotics (Table 2) [7,31,32]. The tested antibiotics exhibited activity with the range of MIC from 0.125 to 16.0 µg/mL in the case of staphylococci.
Up to the concentration of 32 µg/mL, no activity was observed against both investigated reference strains of Gram-negative bacteria, namely E. coli ATCC 25,922 and P. aeruginosa ATCC 27,853 nor the human pathogenic yeasts of the Candida genus. Our research revealed also lower activity of investigated antibiotics against Gram-negative bacteria. Six out of seven tested antibiotics did not affect E. coli and P. aeruginosa up to the highest tested concentration—32.0 µg/mL. The high antistaphylococcal potential of selected agents was additionally confirmed against clinical isolates of S. aureus. Interestingly, no difference was observed in the susceptibility of MRSA and MSSA strains (Table 3), which is very important from the clinical point of view. Five of these substances inhibited the growth of all strains tested at the concentration not higher than 1 µg/mL. The four most active compounds, namely 32–34, and 36 were selected for further tests.
Several research groups also synthesized heterocyclic compounds of similar structures. However, according to our best knowledge, none of those compounds exhibited comparable antistaphylococcal activity (MIC values below 1 µg/mL) [33,34,35,36]. Moreover, the results presented by other authors did not indicate similar selectivity of antimicrobial properties (high activity against Gram-positive bacteria and no activity against both Gram-negative bacteria and human pathogenic yeasts) [33,34,35]. In some cases, it is difficult to compare results, because different method of determination of antimicrobial activity (disc diffusion) was used by the authors [33,34].

2.2.2. Bactericidal Effect of Selected Compounds

The structures of four compounds selected for further analysis, namely 32, 33, 34 and 36, are similar. Despite this fact, the kinetic time—kill assay revealed some important differences in the activity of these substances. The respective curves are shown in Figure 3. Compound 33 was apparently bacteriostatic only and did not exhibit any bactericidal effect, while the other three demonstrated a clear such effect, i.e., their action resulted in some reduction of the cell number, even in the case of its concentrations 2 or 4 times higher than MIC. Undoubtedly, compound 34 was the most effective in this respect. A substantial reduction of the log10 CFU value (from 6 to 0) of the bacterial cell suspension was observed at 4 × MIC after 1 h-long treatment with this compound and at 2 × MIC after 3 h-long treatment. In the case of compound 36, such reduction of the cell number was achieved only at 4 × MIC after 1 h-long treatment. The action of compound 32 resulted in a maximal reduction of log10 CFU from 6 to 2 after 6 h-long treatment at 4 × MIC. Therefore, the bactericidal potential of compounds tested ranks them in the 34 > 36 > 32 order, whereas compound 33 was not bactericidal at all. For all four compounds, the re-growth of bacterial cells was observed after 24 h-long treatment. This observation indicates that even in the cases when the reduction of log10 CFU from 6 to 0 was noted after shorter treatments, some residual live cells must have been preserved.

2.2.3. Activity of the Selected Compounds against Staphylococcal Biofilm

When the S. aureus cells were grown in the biofilm mode, the antistaphylococcal potential of compounds 32–34 and 36 appeared much lower, if any, than that found against the cells grown in the planktonic mode. None of these compounds caused any decrease in the metabolic activity of the cells forming the biofilm, as measured with the MTT assay, at concentrations as high as 64 µg/mL (128 or 256 × MIC). It is not especially surprising, since many earlier reports indicated that for different antibacterial agents, their effective concentrations inhibiting metabolic activity of staphylococci grown in the biofilm mode can be 10–1000 times higher than those inhibiting the planktonic growth [37]. This is because the embedded bacterial cells are getting an optimal defense mechanism against the adverse effects of antibiotics and the immune system of the host [37]. Thus in our opinion, the evidentially lower activity against biofilm should not be considered as a crucial disadvantage of the synthesized compounds.

2.2.4. Influence of the Selected Compounds on Metabolic Activity

When a semi-quantitative API ZYM micro-method was applied for the determination of influence of the selected compounds on activity of 19 hydrolases of S. aureus, it appeared that the S. aureus ATCC 29,213 reference strain exhibited activity of 5 enzymes, namely alkaline phosphatase, esterase (C4), esterase lipase (C8), acid phosphatase and naphthol-AS-BI-phosphohydrolase. Analysis of the enzymatic activity of bacterial cells treated with the selected agents at ½ × MIC, results of which are shown in Table 4, revealed a statistically significant decrease in the activity of alkaline phosphatase, esterase (C4) and esterase lipase (C8). The activity of two other enzymes was not affected.
In order to explain whether the observed reduction of activity of some enzymes could be a consequence of the killing of bacterial cells, the determination of CFU number in treated and control samples was performed. No difference was observed (no killing effect in the presence of the agents at a concentration of ½ MIC during 1 h incubation was observed). It clearly indicates that treatment of the cells with the selected substances (at a concentration lower than MIC) importantly affected the activity of some of the important enzymes, however without any lethal effect.
Therefore, the outcomes of our biological investigation revealed the very high antistaphylococcal activity against S. aureus ATCC 25923, S. aureus ATCC 29,213 and S. epidermidis ATCC12228 of some synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones at the concentration of 0.125–0.5 µg/mL, while randomly selected antibiotics have MIC in the range of 0.125–8.0 µg/mL. The high antistaphylococcal potential of the most active compounds, namely 32–34 and 36, has been also confirmed against clinical isolates of S. aureus, including the MRSA strains. The obtained results create the prospect of their further in-depth studies as effective antibacterial agents.

3. Materials and Methods

3.1. General Information

Melting points were measured in open to air glass capillaries using a B-540 melting point apparatus (Büchi, New Castle, DE, USA) and are uncorrected. Elemental analysis was performed on a 2400 CHN-analyzer (PerkinElmer, Wilmington, DE, USA) and the results were found to be in good agreement with the calculated values. 1H-NMR spectra (400 MHz) and 13C-NMR spectra (100 MHz) were recorded in DMSO-d6 (unless otherwise indicated) on a Mercury-400 spectrometer (Varian, Palo. Alto, CA, USA) with TMS as an internal standard. Mass spectra were recorded on a 1100 Series G1956B LC/MSD SL LCMS system (Agilent, Santa Clara, CA, USA) using electrospray ionization at atmospheric pressure (70 eV). X-ray structural analysis of a single crystal of compound 22 was performed at 173 K on a Smart Apex II diffractometer (Bruker, Madison, WI, USA) operating in the ω scans mode. The intensity data were collected within the range of 2.19 ≤ θ ≤ 26.72° using Mo-Kα radiation (λ = 0.71078 Å). The intensities of 11,753 reflections were collected (2580 unique reflections, Rmerg = 0.0526). The structure was solved by direct methods and refined by the full-matrix least-squares technique in the anisotropic approximation for non-hydrogen atoms using the Bruker SHELXTL program package [38]. All chemicals were of reagent grade and used without further purification. The solvents were purified according to the standard procedures [39]. 1-Amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1) and 1-amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (2) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

3.2. Chemistry

1-Amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (5). To 1-amino-9,10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid (1, 0.5 g, 1.87 mmol) in benzene (30 mL) pyridine (0.023 mL, 0.28 mmol) and thionyl chloride (0.41 mL, 5.61 mmol) were added and the mixture boiled for 5 h at 80 °C with a calcium chloride drying tube. The reaction mixture was cooled to room temperature. The solvent was distilled off under vacuum. The residue was added portionwise to 25% ammonia solution (50 mL) at −15 ° C and kept at this temperature for 1 h. After the mixture was gradually heated to 80 °C, kept at this temperature for 3 h, then cooled to room temperature, acidified with 10% HCl to pH = 6, filtered and washed with water. Compound 3 did not require additional purification. Yield 90%; m.p.: 299–300 °C (298–299 °C in [40]); 1H-NMR: δ = 7.31 (d, 2H, NH2), 7.61 (m, 1HAr), 7.79–7.84 (m, 2H, NH2), 7.98–8.13 (m, 4HAr), 9.05 (s, 1HAr). 13C-NMR: δ = 113.21, 113.31, 121.77, 126.12, 126.45, 132.06, 133.45, 134.26, 134.52, 135.17, 135.68 (CAr), 151.96 (C-NH2); 169.76, 182.43, 183.98 (C=O). LC-MS (70 eV): m/z = 267 [M + 1]+ (100%). Anal. Calcd. for C15H10N2O3: C, 67.67; H, 3.79; N, 10.52. Found: C, 67.75; H, 3.72; N, 10.58.
1-Amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (14). This compound was obtained similarly to 5. Yield 89%; m.p. > 300 °C: 1H-NMR (CF3COOD): δ = 7.56–8.03 (m, 4H, HAr+NH2), 8.11–8.84 (m, 5H, HAr+NH2). 13C-NMR (CF3COOD): δ = 122.38, 125.82, 127.57, 127.72, 132.13, 132.88, 134.31, 135.04, 135.08, 135.67, 136.37 (CAr), 142.13 (C-NH2); 169.92, 182.62, 185.96 (C=O). LC-MS (70 eV): m/z = 346 [M + 1]+ (100%). Anal. Calcd. for C15H9BrN2O3: C, 52.20; H, 2.63; N, 8.12. Found: C, 52.26; H, 2.69; N, 8.17.

3.2.1. General Procedure for the Synthesis of Amides 6–13, 15–21

To the corresponding amino acid 1 or 2 (1.87 mmol) in benzene (30 mL), pyridine (0.023 mL, 0.28 mmol) and thionyl chloride (0.41 mL, 5.61 mmol) were added. The mixture was boiled for 5 h at 80 °C with a calcium chloride drying tube, and then the solvent was distilled off under vacuum. Benzene (30 mL) was added to the resulting residue at room temperature, then the corresponding aniline (2.06 mmol) and triethylamine (0.29 mL, 2.06 mmol) were added (in the case of cyclohexylamine, N,N-diisopropylethylamine was used). The mixture was boiled at 80 °C for 12 h, cooled to room temperature and the solvent was distilled off under vacuum. The resulting precipitate was suspended in water (100 mL), filtered, washed with water (150 mL and dried. If necessary, amides can be recrystallized from acetic acid.
1-Amino-9,10-dioxo-N-(2-(trifluoromethyl)phenyl)-9,10-dihydroanthracene-2-carboxamide (6). Yield 89%; m.p.: 180–182 °C (sublimation); 1H-NMR: δ = 7.49 (d, J = 7.8 Hz, 1HAr), 7.59 (t, J = 8.3 Hz, 2HAr), 7.74–7.93 (m, 5HAr), 8.12 (d, J = 7.3 Hz, 2HAr), 8.20 (d, J = 7.6 Hz, 1HAr), 8.77 (s, 1HAr), 10.42 (br.s, 1H, NH). 13C-NMR: δ = 114.01, 119.68 (q, J = 32 Hz, C-CF3), 122.65, 125.55 (q, J = 268 Hz, CF3), 126.75, 127.06, 128.32, 131.84, 132.64, 133.70, 134.15, 134.76, 135.17, 135.67, 136.54, 151.94 (CAr); 167.91, 182.98, 184.66 (C=O). LC-MS (70 eV): m/z = 411 [M + 1]+ (100%). Anal. Calcd. for C22H13F3N2O3: C, 64.39; H, 3.19; N, 6.83. Found: C, 64.39; H, 3.15; N, 6.87.
1-Amino-9,10-dioxo-N-(m-tolyl)-9,10-dihydroanthracene-2-carboxamide (7). Yield 91%; m.p.: 225–226 °C; 1H-NMR: δ = 2.31 (s, 3H, CH3), 6.94 (d, J = 6.2 Hz, 1HAr), 7.23 (t, J = 7.0 Hz, 1HAr), 7.43–7.63 (m, 5H, HAr+NH2), 7.86 (dd, J = 22.9, 6.0 Hz, 2HAr), 8.02-8.22 (m, 3HAr), 10.39 (br s, 1H, NH). 13C-NMR: δ = 21.68 (CH3), 113.75, 114.14, 118.34, 121.69, 125.30, 126.74, 127.08, 128.95, 132.67, 134.11, 134.80, 135.14, 135.69, 136.13, 138.31, 139.01 (CAr), 166.54, 182.98, 184.63 (C=O). LC-MS (70 eV): m/z = 357 [M + 1]+ (100%). Anal. Calcd. for C22H16N2O3: C, 74.15; H, 4.53; N, 7.86. Found: C, 74.09; H, 4.51; N, 7.91.
1-Amino-N-cyclohexyl-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (8). Yield 91%; m.p.: 289-290 °C (289–290 °C in [40]); 1H-NMR: δ = 1.29 (m, 6H, CH2), 1.59-1.91 (m, 4H, CH2), 3.76 (s, 1H, CH), 7.36 (s, 3HAr, CH+NH2), 7.89 (m, 3HAr), 8.15 (m, 3HAr, CH+NH). 13C-NMR: δ = 25.03, 30.79, 32.66 (CH2), 48.76 (CH), 114.16, 127.07, 128.80, 132.69, 134.12, 135.17, 135.75, 135.82, 151.74 (CAr), 166.91, 183.07, 184.59 (C=O). LC-MS (70 eV): m/z = 349 [M + 1]+ (100%). Anal. Calcd. for C21H20N2O3: C, 72.40; H, 5.79; N, 8.04. Found: C, 72.45; H, 5.75; N, 8.01.
1-Amino-N-(3-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (9). Yield 90%; m.p.: 240–242 °C; 1H-NMR: δ = 6.95 (t, J = 7.6 Hz, 1HAr), 7.32–7.54 (m, 4H, HAr+NH2), 7.69 (d, J = 11.4 Hz, 1HAr), 7.80–7.93 (m, 3HAr), 8.07 (dd, J = 21.4, 6.6 Hz, 2HAr), 8.15–8.20 (m, 1HAr), 10.63 (s, 1H, NH). 13C-NMR: δ = 113.83, 114.07, 116.78, 124.05, 126.74, 127.08, 130.70, 130.77, 132.64, 134.15, 134.76, 135.17, 135.80, 136.32, 140.81, 151.59 (CAr), 162.49 (d, J = 241.1 Hz, C-F), 166.78, 182.96, 184.65 (C=O). LC-MS (70 eV): m/z = 361 [M + 1]+ (100%). Anal. Calcd. for C21H13FN2O3: C, 70.00; H, 3.64; N, 7.77. Found: C, 70.03; H, 3.60; N, 7.74.
1-Amino-N-(4-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (10). Yield 88%; m.p.: 262–264 °C; 1H-NMR: δ = 7.19 (s, 2HAr), 7.32–7.44 (m, 2H, NH2), 7.73 (s, 2HAr), 7.83 (d, J = 28.3 Hz, 3HAr), 8.01–8.09 (m, 2H), 8.13–8.17 (m, 1HAr), 10.50 (br s, 1H, NH). 13C-NMR: δ = 116.08, 117.89, 124.37, 125.17, 125.50, 126.27, 129.05, 130.95, 134.78, 136.28, 136.92, 137.30, 137.72, 138.34, 153.78 (CAr), 161.19 (d, J = 241.4, C-F), 168.64, 185.11, 186.77 (C=O). LC-MS (70 eV): m/z = 361 [M + 1]+ (100%). Anal. Calcd. for C21H13FN2O3: C, 70.00; H, 3.64; N, 7.77. Found: C, 69.98; H, 3.61; N, 7.79.
1-Amino-N-(3-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (11). Yield 87%; m.p.: 252–253 °C; 1H-NMR (CF3COOD): δ = 7.39–7.45 (m, 4HAr), 7.67 (s, 1H), 8.05 (m, 2HAr), 8.44 (d, J = 11.0 Hz, 4HAr), 8.56 (d, J = 7.4 Hz, 1HAr), 11.52 (s, 1H, NH). 13C-NMR (CF3COOD): δ = 116.95, 123.90, 125.89, 128.14, 130.79, 131.25, 132.20, 133.49, 135.10, 135.27, 135.91, 137.39, 138.17, 139.03, 139.62, 140.06 (CAr), 168.73, 185.40, 189.75 (C=O). LC-MS (70 eV): m/z = 377 [M + 1]+ (100%). Anal. Calcd. for C21H13ClN2O3: C, 66.94; H, 3.48; N, 7.43. Found: C, 66.99; H, 3.43; N, 7.45.
1-Amino-N-(4-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (12). Yield 89%; m.p.: 265–266 °C; 1H-NMR (CF3COOD): δ = 7.38–7.45 (m, 4H, HAr+NH2), 7.97 (m, 3HAr), 8.33–8.39 (m, 4HAr), 8.70 (s, 1HAr), 11.51 (s, NH). 13C-NMR (CF3COOD): δ = 123.77, 124.02, 125.43, 128.38, 129.52, 129.67, 130.43, 131.52, 132.04, 132.84, 132.91, 133.07, 133.96, 134.46, 136.29, 136.57, 136.89 (CAr), 165.69, 182.76, 186.67 (C=O). LC-MS (70 eV): m/z = 377 [M + 1]+ (100%). Anal. Calcd. for C21H13ClN2O3: C, 66.94; H, 3.48; N, 7.43. Found: C, 66.93; H, 3.50; N, 7.41.
1-Amino-N-(2-methoxyphenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (13). Yield 89%; m.p.: 187–189 °C [41]; 1H-NMR (CF3COOD): δ = 3.90 (s, 3H, OCH3), 7.03 (t, J = 7.4 Hz, 2HAr), 7.30 (t, J = 8.3 Hz, 1HAr), 7.77 (d, J = 7.6 Hz, 1HAr), 7.97 (m, 3HAr), 8.38 (m, 3HAr), 8.47 (d, J = 8.2 Hz, 1HAr), 8.71 (d, J = 8.2 Hz, 1HAr), 11.52 (s, NH). 13C-NMR (CF3COOD): δ = 55.09 (CH3), 111.43, 121.19, 123.10, 123.37, 127.85, 128.29, 128.86, 129.71, 131.28, 131.93, 132.81, 133.17, 134.20, 136.22, 136.49 (CAr), 151.10, 182.68, 186.54 (C=O). LC-MS (70 eV): m/z = 373 [M + 1]+ (100%). Anal. Calcd. for C22H16N2O4: C, 70.96; H, 4.33; N, 7.52. Found: C, 70.92; H, 4.30; N, 7.56.
1-Amino-4-bromo-N-(3-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (15). Yield 90%; m.p.: 253–255 °C; 1H-NMR: δ = 6.95 (s, 1HAr), 7.34–7.47 (m, 4H, NH2+HAr), 7.77–7.84 (m, 3HAr), 8.04 (d, J = 20.7 Hz, 2H), 8.15 (m, 1HAr), 10.72 (s, 1H, NH). 13C-NMR: δ = 126.53, 126.77, 130.76, 133.18, 133.47, 133.73, 134.22, 134.73, 141.77, 151.05 (CAr), 162.44 (d, J = 241.0 Hz, C-F), 165.25, 182.37, 184.04 (C=O). LC-MS (70 eV): m/z = 440 [M + 1]+ (100%). Anal. Calcd. for C21H12BrFN2O3: C, 57.42; H, 2.75; N, 6.38. Found: C, 57.47; H, 2.71; N, 6.43.
1-Amino-4-bromo-N-(2-methoxyphenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (16). Yield 91%; m.p.: 225–226 °C; 1H-NMR: δ = 3.83 (s, 3H, CH3), 6.95-7.38 (m, 4HAr), 7.52–7.66 (m, 1HAr), 7.79–7.93 (m, 2H, NH2), 8.06-8.24 (m, 3HAr), 8.84 (m, 1H), 10.03 (s, 1H, NH). 13C-NMR: δ = 56.20 (CH3), 106.33, 112.19, 120.63, 126.23, 126.45, 126.61, 126.84, 127.34, 128.80, 133.32, 133.41, 133.87, 134.31, 134.83, 141.82, 151.18, 153.00 (CAr), 161.38, 182.57, 184.15 (C=O). LC-MS (70 eV): m/z = 452 [M + 1]+ (100%). Anal. Calcd. for C22H15BrN2O4: C, 58.55; H, 3.35; N, 6.21. Found: C, 58.59; H, 3.31; N, 6.24.
1-Amino-4-bromo-N-cyclohexyl-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (17). Yield 89%; m.p.: >300 °C (298–299 °C in [40]); 1H-NMR: δ = 1.29 (m, 5H, CH2), 1.78 (m, 5H, CH2), 3.73 (m, 1H, CH), 7.35 (s, 1HAr), 7.81–7.88 (s, 2H, NH2), 7.99–8.13 (m, 4HAr), 8.65 (s, 1HAr). 13C-NMR: δ = 25.32, 25.68, 32.58 (CH2), 48.90 (CH), 124.81, 126.52, 126.59, 126.80, 128.81, 129.22, 133.02, 133.25, 133.83, 134.21, 134.76, 141.22 (CAr), 165.46, 182.50, 182.63 (C=O). LC-MS (70 eV): m/z = 428 [M + 1]+ (100%). Anal. Calcd. for C21H19BrN2O3: C, 59.03; H, 4.48; N, 6.56. Found: C, 59.00; H, 4.51; N, 6.59.
1-Amino-4-bromo-N-(4-fluorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (18). Yield 87%; m.p.: 273–275 °C; 1H-NMR: δ = 7.19 (s, 2HAr), 7.71 (s, 2H, NH2), 7.81 (s, 3HAr), 8.05 (d, J = 22.5 Hz, 3HAr), 8.15 (s, 1HAr), 10.61 (s, 1H, NH). 13C-NMR: δ = 106.32, 115.82, 123.09, 123.26, 124.84, 126.53, 126.77, 133.20, 133.75, 134.22, 134.73, 141.68, 150.98 (CAr), 159.15 (d, J = 241.1 Hz, C-F), 164.97, 182.39, 184.04 (C=O). LC-MS (70 eV): m/z = 440 [M + 1]+ (100%). Anal. Calcd. for C21H12BrFN2O3: C, 57.42; H, 2.75; N, 6.38. Found: C, 57.46; H, 2.71; N, 6.43.
1-Amino-4-bromo-N-(3-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (19). Yield 90%; m.p.: 243–245 °C; 1H-NMR (CF3COOD): δ = 7.21–7.44 (m, 4H, HAr+NH2), 7.80–8.05 (m, 4HAr), 8.21–8.39 (m, 3HAr), 11.51 (1H, NH). 13C-NMR (CF3COOD): δ = 119.06, 119.96, 120.91, 122.20, 124.11, 126.23, 126.70, 127.14, 129.32, 130.63, 132.35, 133.91, 135.05, 137.34, 138.29, 141.87, 150.38 (CAr), 166.14, 182.88, 184.50 (C=O). LC-MS (70 eV): m/z = 456 [M + 1]+ (100%). Anal. Calcd. for C21H12BrClN2O3: C, 55.35; H, 2.65; N, 6.15. Found: C, 55.39; H, 2.61; N, 6.18.
1-Amino-4-bromo-N-(4-chlorophenyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (20). Yield 87%; m.p.: 255–256 °C; 1H-NMR: δ = 7.44 (d, J = 8.6 Hz, 2HAr), 7.76 (d, J = 8.6 Hz, 2HAr), 7.85–7.92 (m, 4HAr), 8.10 (d, J = 7.2 Hz, 1HAr), 8.17 (d, J = 7.5 Hz, 1HAr), 8.20 (s, 1HAr), 10.74 (s, 1H, NH). 13C-NMR: δ = 115.14, 122.27, 124.52, 126.08, 126.31, 127.94, 128.55, 132.76, 132.97, 133.30, 133.79, 137.34, 141.25, 150.48 (CAr), 164.60, 181.99, 183.64 (C=O). LC-MS (70 eV): m/z = 456 [M + 1]+ (100%). Anal. Calcd. for C21H12BrClN2O3: C, 55.35; H, 2.65; N, 6.15. Found: C, 55.33; H, 2.62; N, 6.13.
1-Amino-4-bromo-9,10-dioxo-N-(2-(trifluoromethyl)phenyl)-9,10-dihydroanthracene-2-carboxamide (21). Yield 89%; m.p.: 285–286 °C (sublimation); 1H-NMR: δ = 7.56–7.66 (m, 2HAr), 7.76 (d, J = 7.6 Hz, 1HAr), 7.82 (d, J = 8.0 Hz, 1HAr), 7.88-7.91 (m, 2HAr), 8.13 (d, J = 7.5 Hz, 2HAr), 8.20 (d, J = 7.7, 1HAr), 8.28 (s, 1HAr), 8.84 (s, 1HAr), 10.48 (s, 1H, NH). 13C-NMR: δ = 116.12, 119.76 (q, J = 35.2 Hz, C-CF3), 123.86, 124.55 (q, J = 268 Hz, CF3), 126.61, 126.82, 128.35, 131.61, 133.41, 133.63, 133.95, 134.28, 134.77, 141.82, 151.38 (CAr), 166.55, 182.52, 184.22 (C=O). LC-MS (70 eV): m/z = 490 [M + 1]+ (100%). Anal. Calcd. for C22H12BrF3N2O3: C, 54.01; H, 2.47; N, 5.73. Found: C, 54.04; H, 2.43; N, 5.76.

3.2.2. General Procedure for the Synthesis of Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38

To the corresponding amide 5–13 (1.88 mmol) in glacial acetic acid (50 mL) (in the case of amides 14–21 100–150 mL of glacial acetic acid was used), a first portion of NaNO2 (0.168 g, 2.44 mmol) in water (1.5 mL) was added with the stirring at room temperature, After 3 h, the same amount of NaNO2 in water (1.5 mL) was added. The mixture was stirred for 9 h at room temperature and then filtered. The filtrate was poured into water (200 mL, in the case of amides 14–21 600 mL of water), acidified with a 10% HCl solution to pH = 6. The resulting precipitate was filtered off, washed with water and dried in air.
Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (22). Yield 90%; m.p.: 140-142 °C (decomposition); 1H-NMR: δ = 7.88–7.91 (m, 2HAr), 8.10 (m, 2HAr), 8.49–8.33 (m, 2HAr), 15.38 (1H, br s, NH). 13C-NMR: δ = 124.43, 126.82, 127.17, 129.57, 130.39, 132.19, 134.58, 135.17, 135.53, 139.03, 141.94 (CAr); 155.22, 182.04, 182.28 (C=O). LC-MS (70 eV): m/z = 278 [M + 1]+ (100%). Anal. Calcd. for C15H7N3O3: C, 64.99; H, 2.55; N, 15.16. Found: C, 65.01; H, 2.51; N, 15.19.
Crystallography: X-ray structure determination of compound22. Crystal data for 22: C15H7N3O4 ˣH2O, M = 295.25, monoclinic, space group P21/c, a = 7.070(3), b = 12.687(5), c = 13.816(5) Å, β = 95.842(11)°, V = 1232.9(8)Å3, Z = 4, dc = 1.591 g·cm−3, μ = 0.119 mm−1, F(000) = 608, crystal size ca. 0.09 × 0.11 × 0.50 mm. All CH hydrogen atoms were placed at calculated positions and refined as ‘riding’ model and NH hydrogen atom was located at DF synthesis and refined isotropically. Convergence was obtained at R1 = 0.0613 and wR2 = 0.1134 for 1319 observed reflections with I ≥ 2σ(I), R1 = 0.1465 and wR2 = 0.1474, GOF = 1.039 for 2580 independent reflections, 211 parameters, the largest and minimal peaks in the final difference map 0.18 and −0.18 e/Å3. Full crystallographic details have been deposited at Cambridge Crystallographic Data Centre (CCDC). Any request to the CCDC for these materials should quote the full literature citation and reference number CCDC 1966785.
3-(2-(Trifluoromethyl)phenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (23). Yield 72%; m.p.: 225–226 °C (decomposition); 1H-NMR (400 MHz, DMSO-d6): δ = 7.89 (t, J = 7.5 Hz, 1HAr), 7.94–8.01 (m, 4HAr), 8.06 (d, J = 7.8 Hz, 1HAr), 8.20 (d, J = 7.4 Hz, 2HAr), 8.69 (d, J = 8.2 Hz, 1HAr), 8.74 (d, J = 8.2 Hz, 1HAr). 13C-NMR (100 MHz, DMSO-d6): δ = 119.01 (q, J = 32 Hz, C-CF3), 122.44, 123.81, 124.46, 125.03 (q, J = 273 Hz, CF3), 126.42, 126.91, 127.27, 127.98, 129.84, 130.99, 131.70, 132.38, 134.73, 135.26, 135.56, 136.33, 139.54, 140.84 (CAr); 154.80, 182.00, 182.14 (C=O). LC-MS (70 eV): m/z = 422 [M + 1]+ (100%). Anal. Calcd. for C22H10F3N3O3: C, 62.72; H, 2.39; N, 9.97. Found: C, 62.67; H, 2.43; N, 10.01.
3-(m-Tolyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (24). Yield 73%; m.p.: 230-231 °C (decomposition); 1H-NMR: δ = 1.90 (s, 3H, CH3), 7.39-7.60 (m, 3HAr), 7.88–8.03 (m, 3HAr), 8.20 (d, J = 8.4 Hz, 2HAr), 8.59-8.76 (m, 2HAr). 13C-NMR: δ = 124.02, 124.41, 126.90, 127.25, 127.30, 129.32, 129.40, 130.33, 130.97, 132.35, 134.68, 135.13, 135.19, 135.57, 138.92, 139.09, 140.87 (CAr); 154.41, 182.04, 182.26 (C=O). LC-MS (70 eV): m/z = 368 [M + 1]+ (100%). Anal. Calcd. for C22H13N3O3: C, 71.93; H, 3.57; N, 11.44. Found: C, 71.97; H, 3.52; N, 11.46.
3-Cyclohexylanthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (25). Yield 71%; m.p.: 215 °C (decomposition); 1H-NMR: δ = 1.54 (dd, J = 36.6, 9.0 Hz, 4H, CH2), 1.88-2.08 (m, 6H, CH2), 4.82-4.95 (m, 1H, CH), 7.86–7.97 (m, 2HAr), 8.12 (s, 2HAr), 8.45–8.60 (m, 2HAr). 13C-NMR: δ = 25.45, 25.71, 31.81 (CH2), 57.02 (C-H), 123.12, 126.84, 127.25, 129.00, 129.73, 130.88, 131.93, 133.44, 134.61, 135.54, 138.90, 140.94 (CAr); 153.92, 181.97, 182.28 (C=O). LC-MS (70 eV): m/z = 360 [M + 1]+ (100%). Anal. Calcd. for C21H17N3O3: C, 70.18; H, 4.77; N, 11.69. Found: C, 70.21; H, 4.74; N, 11.72.
3-(3-Fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (26). Yield 69%; m.p.: 225 °C (decomposition); 1H-NMR: δ = 7.39–7.49 (m, 1HAr), 7.58–7.73 (m, 3HAr), 7.91–7.99 (m, 2HAr), 8.15–8.23 (m, 2HAr), 8.59–8.74 (m, 2HAr). 13C-NMR: δ = 116.61, 116.78, 123.21, 124.40, 126.93, 127.27, 127.32, 129.46, 130.50, 130.96, 131.29, 132.40, 134.70, 135.22, 135.57, 140.74 (CAr), 162.12 (d, J = 246.0 Hz, C-F), 154.39, 182.03, 182.22 (C=O). LC-MS (70 eV): m/z = 372 [M + 1]+ (100%). Anal. Calcd. for C21H10FN3O3: C, 67.93; H, 2.71; N, 11.32. Found: C, 67.96; H, 2.68; N, 11.36.
3-(4-Fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (27). Yield 75%; m.p.: 230–232 °C (decomposition); 1H-NMR: δ = 7.42–7.56 (m, 2HAr), 7.74–7.85 (m, 2HAr), 7.89–8.03 (m, 3H), 8.11–8.25 (m, 2H), 8.66 (d, J = 30.3 Hz, 1H). 13C-NMR (100 MHz, CF3COOD): δ = 111.43, 116.21, 124.69, 128.37, 128.58, 130.15, 131.54, 131.78, 134.51, 134.69, 136.54, 137.13, 140.00, 142.25 (CAr), 162.05 (d, J = 248.6 Hz, C-F), 160.19, 178.17, 178.75 (C=O). LC-MS (70 eV): m/z = 372 [M + 1]+ (100%). Anal. Calcd. for C21H10FN3O3: C, 67.93; H, 2.71; N, 11.32. Found: C, 67.89; H, 2.73; N, 11.29.
3-(3-Chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (28). Yield 69%; m.p.: 233 °C (decomposition); 1H-NMR (CF3COOD): δ = 7.29 (d, J = 7.6 Hz, 1HAr), 7.35 (t, J = 8.0 Hz, 1HAr), 7.41 (d, J = 7.8 Hz, 1HAr), 7.64 (s, 1HAr), 8.00–8.03 (m, 2HAr), 8.44 (dd, J = 11.4 Hz, 8.7, 2HAr), 8.85 (d, J = 8.2 Hz, 1HAr), 9.23 (d, J = 8.2 Hz, 1HAr). 13C-NMR (CF3COOD): δ = 111.50, 120.29, 122.43, 128.04, 128.45, 128.66, 130.39, 131.60, 131.86, 134.51, 134.78, 135.52, 136.62, 137.19, 140.08, 142.35 (CAr), 160.02, 178.23, 178.80 (C=O). LC-MS (70 eV): m/z = 388 [M + 1]+ (100%). Anal. Calcd. for C21H10ClN3O3: C, 65.05; H, 2.60; N, 10.84. Found: C, 65.08; H, 2.56; N, 10.81.
3-(4-Chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (29). Yield 67%; m.p.: 251 °C (decomposition); 1H-NMR (CF3COOD): δ = 7.39 (d, J = 7.3 Hz, 2HAr), 7.52 (d, J = 7.0 Hz, 2HAr), 8.00–8.05 (m, 2HAr), 8.41–8.47 (m, 2HAr), 8.82–8.90 (m, 1HAr), 9.20–9.27 (m, 1HAr). 13C-NMR (CF3COOD): δ = 111.42, 123.52, 128.38, 128.59, 129.47, 131.55, 131.78, 132.89, 134.51, 134.71, 136.55, 137.09, 137.17, 140.02, 142.34 (CAr), 159.89, 178.17, 178.76 (C=O). LC-MS (70 eV): m/z = 388 [M + 1]+ (100%). Anal. Calcd. for C21H10ClN3O3: C, 65.05; H, 2.60; N, 10.84. Found: C, 65.02; H, 2.58; N, 10.86.
3-(2-Methoxyphenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (30). Yield 78%; m.p.: 216 °C (decomposition); 1H-NMR (CF3COOD): δ = 3.90 (s, 3H, CH3), 7.06 (d, J = 8.1 Hz, 1HAr), 7.33 (t, J = 7.8 Hz, 1HAr), 7.80 (d, J = 7.8 Hz, 1HAr), 8.00–8.03 (m, 3HAr), 8.44 (dd, J = 10.8 Hz, 8.9 Hz, 2HAr), 8.82 (d, J = 8.1 Hz, 1HAr), 9.24 (d, J = 8.2 Hz, 1HAr). 13C-NMR (CF3COOD): δ = 55.18 (CH3), 111.51, 121.27, 123.01, 123.48, 128.64, 131.58, 131.85, 134.44, 134.73, 136.60, 137.11, 137.23, 140.13, 142.59 (CAr);, 151.26 (C-OMe), 159.80, 178.24, 178.81 (C=O). LC-MS (70 eV): m/z = 384 [M + 1]+ (100%). Anal. Calcd. for C22H13N3O4: C, 68.93; H, 3.42; N, 10.96. Found: C, 68.95; H, 3.39; N, 10.99.
6-Bromoanthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (31). Yield 78%; m.p.: 155 °C (decomposition); 1H-NMR: δ = 7.92 (d, J = 3.4 Hz, 2HAr), 8.08 (d, J = 8.8 Hz, 2HAr), 8.67 (s, 1HAr), 15.45 (br s, 1H, NH). 13C-NMR: δ = 123.54, 124.15, 126.32, 126.93, 133.50, 134.41, 134.67, 135.00, 135.72, 141.04 (CAr); 153.96, 181.71, 181.94 (C=O). LC-MS (70 eV): m/z = 357 [M + 1]+ (100%). Anal. Calcd. for C15H6BrN3O3: C, 50.59; H, 1.70; N, 11.80. Found: C, 50.62; H, 1.67; N, 11.83.
6-Bromo-3-(3-fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (32). Yield 65%; m.p.: 235–237 °C (decomposition); 1H-NMR: δ = 7.37–7.52 (m, 1HAr), 7.65 (m, 2HAr), 7.87–8.02 (m, 2HAr), 8.08–8.30 (m, 3HAr), 8.62–8.91 (m, 1HAr). 13C-NMR (CF3COOD): δ = 109.25, 109.46, 109.81, 114.55, 114.73, 117.37, 128.11, 128.52, 130.73, 132.79, 134.91, 135.71, 135.99, 137.69, 139.56, 140.02, 141.82 (CAr), 163.11 (d, J = 246.5 Hz, C-F), 159.03, 177.56, 178.28 (C=O). LC-MS (70 eV): m/z = 451 [M + 1]+ (100%). Anal. Calcd. for C21H9BrFN3O3: C, 56.02; H, 2.01; N, 9.33. Found: C, 56.05; H, 1.99; N, 9.36.
6-Bromo-3-(2-methoxyphenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (33). Yield 67%; m.p.: 240 °C (decomposition); 1H-NMR: δ = 3.80 (s, 3H, CH3), 7.17–7.34 (m, 2HAr), 7.56–7.64 (m, 2HAr), 7.95 (s, 2HAr), 8.11–8.20 (m, 2HAr), 8.80 (s, 1HAr). 13C-NMR: δ = 56.44 (CH3), 113.14, 121.25, 123.51, 124.66, 126.42, 127.01, 127.31, 129.40, 132.12, 133.69, 134.46, 134.76, 135.03, 136.90, 140.07 (CAr); 152.80 (C-OMe), 154.86, 181.68, 181.89 (C=O). LC-MS (70 eV): m/z = 463 [M + 1]+ (100%). Anal. Calcd. for C22H12BrN3O4: C, 57.16; H, 2.62; N, 9.09. Found: C, 57.12; H, 2.66; N, 9.05.
6-Bromo-3-cyclohexylanthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (34). Yield 65%; m.p.: 242–243 °C (decomposition); 1H-NMR: δ = 1.20–1.54 (m, 6H, CH2), 1.69–1.95 (m, 4H, CH2), 4.82–4.93 (m, 1H, CH), 7.92 (s, 2HAr), 8.08 (s, 2HAr), 8.66 (s, 1HAr). 13C-NMR: δ = 25.40, 25.66, 31.71 (CH2), 57.22 (CH), 122.76, 123.65, 126.31, 126.91, 132.99, 133.40, 134.26, 134.69, 134.99, 136.37, 139.94 (CAr); 152.58, 181.58, 181.71 (C=O). LC-MS (70 eV): m/z = 439 [M + 1]+ (100%). Anal. Calcd. for C21H16BrN3O3: C, 57.55; H, 3.68; N, 9.59. Found: C, 57.58; H, 3.64; N, 9.62.
6-Bromo-3-(4-fluorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (35). Yield 67%; m.p.: 223 °C (decomposition); 1H-NMR: δ = 7.48 (dd, J = 9.2 Hz, 4.7 Hz, 2HAr), 7.72–7.79 (m, 2HAr), 7.90–7.98 (m, 2HAr), 8.11–8.18 (m, 2HAr), 8.78 (s, 1HAr). 13C-NMR: δ = 109.84, 116.16, 116.35, 124.36, 124.43, 128.15, 128.55, 130.18, 130.32, 132.84, 134.97, 137.55, 137.71, 139.52, 140.04, 141.91 (CAr), 162.08 (d, J = 248.7 Hz, C-F), 159.32, 177.61, 178.30 (C=O). LC-MS (70 eV): m/z = 451 [M + 1]+ (100%). Anal. Calcd. for C21H9BrFN3O3: C, 56.02; H, 2.01; N, 9.33. Found: C, 56.05; H, 1.97; N, 9.36.
6-Bromo-3-(3-chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (36). Yield 65%; m.p.: 211 °C (decomposition); 1H-NMR (CF3COOD): δ = 7.27 (d, J = 7.8 Hz, 1HAr), 7.33 (t, J = 7.9 Hz, 1HAr), 7.39 (d, J = 7.6 Hz, 1HAr), 7.63 (s, 1HAr), 7.98 (m, 2HAr), 8.35–8.40 (m, 2HAr), 9.02 (s, 1HAr). 13C-NMR (CF3COOD): δ = 119.98, 122.10, 127.93, 128.18, 128.56, 130.34, 130.37, 135.48, 135.60, 136.06, 137.58, 137.73, 140.05, 141.90 (CAr), 159.04, 177.61, 178.24 (C=O). LC-MS (70 eV): m/z = 467 [M + 1]+ (100%). Anal. Calcd. for C21H9BrClN3O3: C, 54.05; H, 1.94; N, 9.00. Found: C, 54.08; H, 1.98; N, 9.03.
6-Bromo-3-(4-chlorophenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (37). Yield 63%; m.p.: 223 °C (decomposition); 1H-NMR (CF3COOD): δ = 7.40 (d, J = 8.4 Hz, 2HAr), 7.53 (d, J = 8.5 Hz, 2HAr), 8.00 (d, J = 6.9 Hz, 1HAr), 8.04 (d, J = 7.4 Hz, 1HAr), 8.41 (d, J = 7.8 Hz, 2HAr), 9.05 (s, 1HAr). 13C-NMR (CF3COOD): δ = 123.20, 128.14, 128.54, 129.50, 130.30, 132.80, 132.92, 133.99, 136.02, 137.54, 139.54, 139.98, 141.85 (CAr), 159.02, 177.59, 178.27 (C=O). LC-MS (70 eV): m/z = 467 [M + 1]+ (100%). Anal. Calcd. for C21H9BrClN3O3: C, 54.05; H, 1.94; N, 9.00. Found: C, 54.03; H, 1.97; N, 9.02.
6-Bromo-3-(2-(trifluoromethyl)phenyl)anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-trione (38). Yield 75%; m.p.: 242 °C (decomposition); 1H-NMR (CF3COOD): δ = 7.66 (d, J = 7.8 Hz, 1HAr), 7.72–7.78 (m, 1HAr), 7.89 (s, 1HAr), 8.04 (m, 3HAr), 8.42 (d, J = 7.7 Hz, 2HAr), 9.08 (s, 1HAr). 13C-NMR (CF3COOD): δ = 119.52 (q, J = 32 Hz, C-CF3), 122.44, 123.81, 124.46, 125.32 (q, J = 273.05 Hz, CF3), 126.42, 126.91, 127.27, 127.98, 129.84 130.70, 131.48, 131.70, 132.38, 134.73, 135.26, 136.33, 139.54, 140.84 (CAr); 154.87, 177.63, 178.24 (C=O). LC-MS (70 eV): m/z = 501 [M + 1]+ (100%). Anal. Calcd. for C22H9BrF3N3O3: C, 52.82; H, 1.81; N, 8.40. Found: C, 52.86; H, 1.83; N, 8.36.

3.3. Biology

3.3.1. Bacterial Strains and Media

The antimicrobial potential of all synthesized compounds was evaluated against five reference strains of bacteria: Staphylococcus aureus ATCC 25923, S. aureus ATCC 29213, S. epidermidis ATCC 12228, Pseudomonas aeruginosa ATCC 27853, and Escherichia coli ATCC 25,922 and four reference strains of human pathogenic yeasts: C. albicans ATCC 10231, C. albicans SC5314, C. krusei DSM 6128 and C. glabrata DSM 11226. Because of the positive results of preliminary tests the anti-staphylococcal activity of selected agents was also investigated against eight MSSA and four MRSA clinical isolates derived from patients with different infections (Table 5). The antibiotics: ampicillin, oxacillin, gentamicin, fusidic acid, levofloxacin, linezolid, daptomycin were purchased from Argenda (Poznan, Poland). Bacteria were routinely grown on Luria-Bertani Agar (LA, Sigma Aldrich, Schnelldorf, Germany) and yeasts were cultivated on YPD Agar (A&A Biotechnology, Gdynia, Poland). In the case of bacteria, the Minimum Inhibitory Concentration (MIC) values were determined using Mueller-Hinton Broth 2 (MHB2, Sigma Aldrich) liquid medium—and determination of the same parameter for yeasts was performed using RPMI 1640 medium (Sigma Aldrich) supplemented with 2% glucose (Sigma Aldrich) and buffered to pH 7.0 with a MOPS buffer (3-N-morpholinopropanesulfonic acid) (Sigma Aldrich). For staphylococcal biofilm formation, TSB (Sigma Aldrich) liquid medium supplemented with 2.5% of glucose was used and Time-Kill assay was performed in Mueller-Hinton Broth 2.

3.3.2. Investigation of Antimicrobial Potential of Synthesized Agents

The two-fold broth microdilution method, according to the CLSI standard methodology [42], was applied for the determination of minimum inhibitory concentrations (MICs) of synthesized agents and antibiotics against bacteria (both reference strains and clinical isolates). Bacterial strains were plated on Luria-Bertani Agar medium and incubated overnight at 37 °C. Two to three bacterial colonies were transferred from the agar medium into PBS buffer (pH = 7.4). The bacterial suspension was adjusted to the optical density of OD600 = 0.1 and diluted in MHB2 medium at a ratio of 1:100 v/v to the final cell concentration of approximately 0.5–1.0 × 106 CFU/mL. The synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones were dissolved in DMSO—final concentration of all substances tested in the stock solutions was 1280 µg/mL. The stock solutions with the same concentration (1280 µg/mL) of all antibiotics were used for investigation. Subsequently, a series of two-fold dilution of each agent in range 64.0–0.0625 µg/mL were prepared in the wells of columns 1–10 of 96-well plates using Mueller-Hinton Broth 2. An aliquot of 100 μL of inoculum was dispensed to the wells of columns 1–11. Column 11 contained 200 µL of inoculum without any agent, and column 12 contained 200 µL of the MHB2 broth only (served as a control of medium sterility). The plates were incubated 24 h under static conditions at 37 °C. The lowest concentration of agent with no visible bacterial growth was taken as a MIC value.
The determination of MIC values for yeast strains was also performed according to the appropriate NCCLS reference microdilution method [43]. The solutions of substances in DMSO were prepared in the same way as for the investigation of antibacterial activity (presented above). Serial two-fold dilutions of the tested substances were prepared in RPMI 1640 medium buffered to pH 7.0 with MOPS buffer (3-N-morpholinopropanesulfonic acid) in 96-well microtiter plates in a final volume of 100 µL. The final concentrations of the agents were in the range from 64 to 0.0625. Suspensions of the microorganisms were prepared by taking one loop of pure culture (cultivated 24 h at 37 °C on YPD agar) into sterile water and adjusting the optical density to 0.1 at 660 nm wavelength before further 50-fold dilution in an RPMI 1640 medium resulting in 2 × 104 CFU/mL. One hundred microliters of such suspension were inoculated to each well of the microtiter plate, leaving a drug-free column (number 12) as sterility controls. Plates were incubated for 24 h at 37 °C. MIC values were read visually as the first concentration where no growth was observed. The MIC assay for each tested strain of bacteria/yeast and agent was performed in triplicate. In the case of both assays (investigation of antibacterial and antifungal activity) the final concentration of the solvent (DMSO) in the medium did not exceed 2.5% (v/v), and did not influence the growth of bacteria/yeast.

3.3.3. Time-Kill Assay

Taking into account the results of previously performed analysis (high activity against staphylococci and lack of activity against Gram-negative bacteria and yeasts) the kinetic time-kill assay was performed for one reference strain of staphylococci (namely S. aureus ATCC 29213) and four, most promising, compounds (namely 32, 33, 34 and 36). The suspension of approx. cell density 0.5–1.0 × 106 CFU/mL of S. aureus ATCC 29,213 was prepared in MHB2 broth supplemented with a particular agent to the final concentrations equal to MIC, 2 × MIC or 4 × MIC and incubated at 37 °C with shaking (150 rpm). Bacterial suspension without agent addition was used as the untreated control. At predetermined time intervals (0, 1, 3, 6 and 24 h) samples were taken, serially diluted in PBS buffer (from 10−1 to 10−7) and spotted (10 µL) onto a Baird-Parker agar plate. After 24 h of incubation, the plates were enumerated. For each agent the assay was repeated in triplicate.

3.3.4. Biofilm Formation and Determination of Antibiofilm Activity

The assay for biofilm cultivation was performed according to the procedure described previously [44] with slight modifications. The suspensions of approx. cell density 1–5 × 108 CFU/mL of S. aureus ATCC 29,213 were diluted 1:100 (v/v) in TSB medium supplemented with 2.5% glucose. Cell suspensions (200 μL) were placed into the wells of columns 1–7 of vertically set plates. The wells of column 8 were fulfilled with 200 μL of sterile medium—these wells were used as a negative control. The plates were incubated for 24 h at 37 °C without shaking in order to allow bacteria to attach. In the next step, the formed biofilm was treated with four selected, most promising agents (32, 33, 34 and 36). The liquid medium was removed from the wells of the plates and the formed biofilm was gently washed with 200 μL of sterile PBS. Subsequently 200 μL of 2-fold serial dilutions of the agents in MHB2 medium, ranging from 64 to 2 µg/mL, were added to the wells of columns 1-6 (column 7—without agent but with formed biofilm served as positive control and wells of column 8—without biofilm, were used as negative control–control of sterility of the medium) and incubated for 24 h at 37 °C. The MTT assay was performed as described previously [44,45]. After 24-h treatment, the liquid content of the wells of the plates was removed and the treated biofilm was washed with 200 μL of sterile PBS buffer. Subsequently, 150 μL of PBS and 50 μL of MTT solution (0.3% in PBS) were added to the wells and mixed. Following 2 h incubation at 37 °C in the dark, the MTT solution was replaced with 200 μL of DMSO for dissolving the formed formazan crystals. The optical density of the obtained solutions was measured at 540 nm using a Victor3 microtiter reader (Perkin Elmer, Waltham, MA, USA). The Minimal Biofilm Eradiation Concentration (MBEC50) values were taken as the lowest concentration of the agent that caused eradication of at least 50% of living cells in comparison to the cells growing in the untreated control—measured as comparison of ability of living cells to the biotransformation of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) to insoluble in water violet formazan crystals [45].

3.3.5. Influence of Investigated Agents on Enzymatic Activity of S. aureus

Fresh suspension (in PBS) of S. aureus ATCC 29,213 OD600 = 0.5 was exposed to the action of the selected tested agents (32, 33, 34 and 36) at concentration equal to ½ MIC for 1 h, 37 °C and then washed three times with PBS in order to avoid ‘carryover’ effect. Next, 65 microliters of the suspension were loaded to the cupules of the API ZYM strips. Suspension of untreated cells of S. aureus ATCC 29,213 served as controls. The strips API ZYM were incubated for 4 h at 37 °C and the results were read according to the manufacturer’s instructions. Enzymatic activity was determined in nanomoles of the hydrolyzed substrate according to the intensity of the color reaction on the scale 1–5, i.e., 1–5 nanomoles, 2–10, 3–20, 4–30, and 5–40 and more nanomoles. The intensity of the color was assessed visually.

4. Conclusions

A convenient method for the preparation of novel anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones is proposed based on the diazotization reaction followed by cyclization of the corresponding 1-amino-9,10-dioxo-9,10-dihydroanthracene-2-carboxamides under acidic conditions at room temperature. The outcomes of our study revealed that some of the synthesized compounds (namely 32–34 and 36) exhibit promising antistaphylococcal activity, which creates the prospect of their further in-depth studies as effective antibacterial agents.

Author Contributions

V.Z.: the synthesis of the compounds, M.S.: interpretation of the results and characterization of all the obtained compounds, writing of original draft. E.R.: the X-ray structure determination and description. M.V.: discussion of the experimental data of chemical part. M.S., V.N.: conceptualization and supervision of synthesis, P.S.: the investigation and interpretation of the antimicrobial activity data, K.G.: investigation of antimicrobial activity, S.M.: conceptualization and supervision of biological studies. All authors participated in review and editing, read and approved the manuscript.

Funding

This research was funded by the Ministry of Education and Science of Ukraine, the bilateral Ukraine-Poland R&D project, agreement № M/42-2019 (Project number: 0119U101928).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hutchings, M.; Truman, A.; Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019, 51, 72–80. [Google Scholar] [CrossRef] [PubMed]
  2. Frieri, M.; Kumar, K.; Boutin, A. Antibiotic resistance. J. Infect. Public Health 2017, 10, 369–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Pristov, K.E.; Ghannoum, M.A. Resistance of Candida to azoles and echinocandins worldwide. Clin. Microbiol. Infect. 2019, 25, 792–798. [Google Scholar] [CrossRef] [PubMed]
  4. Tong, S.Y.; Davis, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G.J. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015, 28, 603–661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Wiggli, B.J.; Frei, R.; Laffer, R.; Tschudin Sutter, S.; Widmer, A.F. Survival from methicillin-sensitive Staphylococcus aureus bloodstream infections over 20 years: A cohort of 1328 patients. Swiss Med. Wkly. 2017, 147, w14508. [Google Scholar] [CrossRef]
  6. Szweda, P.; Schielmann, M.; Kotlowski, R.; Gorczyca, G.; Zalewska, M.; Milewski, S. Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus. Appl. Microbiol. Biotechnol. 2012, 96, 1157–1174. [Google Scholar] [CrossRef] [Green Version]
  7. Grecka, K.; Kuś, P.M.; Okińczyc, P.; Worobo, R.W.; Walkusz, J.; Szweda, P. The anti-staphylococcal potential of ethanolic polish propolis extracts. Molecules 2019, 24, 1732. [Google Scholar] [CrossRef] [Green Version]
  8. Ansari, S.; Jha, R.K.; Mishra, S.K.; Tiwari, B.R.; Asaad, A.M. Recent advances in Staphylococcus aureus infection: Focus on vaccine development. Infect. Drug Resist. 2019, 12, 1243. [Google Scholar] [CrossRef] [Green Version]
  9. Diekema, D.J.; Pfaller, M.A.; Shortridge, D.; Zervos, M.; Jones, R.N. Twenty-Year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program. Open Forum Infect. Dis. 2019, 6 (Suppl. 1), S47–S53. [Google Scholar] [CrossRef]
  10. Kang, J.; Dietz, M.J.; Hughes, K.; Xing, M.; Li, B. Silver nanoparticles present high intracellular and extracellular killing against Staphylococcus aureus. J. Antimicrob. Chemother. 2019, 74, 1578–1585. [Google Scholar] [CrossRef]
  11. Mathur, H.; Field, D.; Rea, M.C.; Cotter, P.D.; Hil, C.; Ross, R.P. Fighting biofilms with lantibiotics and other groups of bacteriocins. npj Biofilms Microbiomes 2018, 4, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Lehman, S.M.; Mearns, G.; Rankin, D.; Cole, R.A.; Smrekar, F.; Branston, S.D.; Morales, S. Design and preclinical development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus Infections. Viruses 2019, 11, 88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Chauhan, D.; Hati, S.; Priyadarshini, R.; Sen, S. Transcriptome analysis predicts mode of action of benzimidazole molecules against Staphylococcus aureus UAMS-1. Drug. Dev. Res. 2019, 80, 1–14. [Google Scholar] [CrossRef] [PubMed]
  14. Subedi, Y.P.; Alfindee, M.N.; Shrestha, J.P.; Chang, C.-W.T. Tuning the biological activity of cationic anthraquinone analogues specifically toward Staphylococcus aureus. Eur. J. Med. Chem. 2018, 157, 683–690. [Google Scholar] [CrossRef]
  15. Zvarych, V.I.; Stasevych, M.V.; Stanko, O.V.; Komarovskaya-Porokhnyavets, E.Z.; Poroikov, V.V.; Rudik, A.V.; Lagunin, A.A.; Vovk, M.V.; Novikov, V.P. Computerized prediction, synthesis, and antimicrobial activity of new amino-acid derivatives of 2-Chloro-N-(9,10-Dioxo-9,10-Dihydroanthracen-1-yl) acetamide. Pharm. Chem. J. 2014, 48, 584–588. [Google Scholar] [CrossRef]
  16. Stasevych, M.; Zvarych, V.; Lunin, V.; Halenova, T.; Savchuk, O.; Dudchak, O.; Vovk, M.; Novikov, V. Novel anthraquinone-based derivatives as potent inhibitors for receptor tyrosine kinases. Indian J. Pharm. Sci. 2015, 77, 634–637. [Google Scholar] [CrossRef] [Green Version]
  17. Stasevych, M.; Zvarych, V.; Lunin, V.; Kopak, N.; Komarovska-Porokhnyavets, O.; Deniz, N.G.; Sayil, C.; Ozyurek, M.; Guclu, K.; Vovk, M.; et al. Synthesis, investigation of antimicrobial and antioxidant activity of anthraquinonylhydrazones. Monatsh. Chem. 2018, 149, 1111–1119. [Google Scholar] [CrossRef]
  18. Kumar, R.; Singh, A.D.; Singh, J.; Singh, H.; Roy, R.K.; Chaudhary, A. 1,2,3-Triazine scaffold as a potent biologically active moiety: A mini review. Mini Rev. Med. Chem. 2014, 14, 72–83. [Google Scholar] [CrossRef]
  19. Kumar, R.; Kumar, N.; Roy, R.K.; Singh, A. Triazines—A comprehensive review of their synthesis and diverse biological importance. Curr. Med. Drug Res. 2017, 1, 173. [Google Scholar]
  20. Kumar, K.S.; Adepu, R.; Sandra, S.; Rambabu, D.; Krishna, G.R.; Reddy, C.M.; Misra, P.; Pal, M. Cu-mediated N-arylation of 1,2,3-triazin-4-ones: Synthesis of fused triazinone derivatives as potential inhibitors of chorismate mutase. Bioorganic. Med. Chem. Lett. 2012, 22, 1146–1150. [Google Scholar] [CrossRef]
  21. Cascioferro, S.; Parrino, B.; Spanò, V.; Carbone, A.; Montalbano, A.; Barraja, P.; Diana, P.; Cirrincione, G. Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives. Eur. J. Med. Chem. 2017, 142, 74–86. [Google Scholar] [CrossRef] [PubMed]
  22. Hamama, W.S.; El-Bana, G.G.; Shaaban, S.; Habib, O.M.O.; Zoorob, H.H. Advances in the domain of 4-amino-3-mercapto-1,2,4-triazine-5-ones. RSC Adv. 2016, 6, 24010–24049. [Google Scholar] [CrossRef]
  23. Srinivasa Rao, D.; Pavan Kumar, G.V.; Pooja, B.; Harika, G.; Anil Kumar, Y.; Sadasiva Rao, G. An extensive review on 1,2,3 and 1,2,4-triazines scaffold-valuable lead molecules with potent and diverse pharmacological activities. Der Chem. Sin. 2016, 7, 101–130. [Google Scholar]
  24. Khalid, Z.; Ahmad, H.A.; Munawar, M.A.; Khan, M.; Gul, S. 1,2,3-Benzotriazin-4(3H)-ones: Synthesis, reactions and applications. Heterocycles 2017, 94, 3–54. [Google Scholar] [CrossRef]
  25. Stasevych, M.; Zvarych, V.; Lunin, V.; Deniz, N.G.; Gokmen, Z.; Akgun, O.; Ulukaya, E.; Poroikov, V.; Gloriozova, T.; Novikov, V. Computer-aided prediction and cytotoxicity evaluation of some dithiocarbamates of 9,10-anthracenedione as new anticancer agents. SAR QSAR Environ. Res. 2017, 28, 355–366. [Google Scholar] [CrossRef]
  26. Stasevych, M.V.; Zvarych, V.I.; Lunin, V.V.; Khomyak, S.V.; Vovk, M.V.; Novikov, V.P. Synthesis of pyrazole and tetrazole derivatives of 9,10-anthraquinonylhydrazones. Chem. Heterocycl. Compd. 2017, 53, 942–944. [Google Scholar] [CrossRef]
  27. Stasevych, M.V.; Zvarych, V.I.; Stan’ko, O.V.; Vovk, M.V.; Novikov, V.P. Synthesis of 2-(N-benzoylimino)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl) thiazoles. Chem. Heterocycl. Compd. 2014, 49, 1831–1833. [Google Scholar] [CrossRef]
  28. Zvarych, V.I.; Stasevych, M.V.; Stan’ko, O.V.; Musyanovych, R.Y.; Novikov, V.P. Amino acid derivatives of 2-chloro-N-(9,10-dioxy-9,10-dihydroanthracen-1-yl) acetamide. Rus. J. Org. Chem. 2014, 50, 306–307. [Google Scholar] [CrossRef]
  29. Zvarych, V.I.; Stasevych, M.V.; Lunin, V.V.; Vovk, M.V.; Novikov, V.P. Synthesis of 9,10-Anthracenedione Diethyldithiocarbamates. Rus. J. Gen. Chem. 2016, 86, 2699–2701. [Google Scholar] [CrossRef]
  30. Stasevych, M.; Zvarych, V.; Musyanovych, R.; Novikov, V.; Vovk, M. Synthesis of N-benzoyl-N’-(9,10-dioxo-9,10-dihydroanthracene-1-yl)-thioureas and quantum-chemical analysis of the reaction passing. Chem. Chem. Technol. 2014, 8, 135–140. [Google Scholar] [CrossRef]
  31. Rubin, J.E.; Ball, K.R.; Chirino-Trejo, M. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus pseudintermedius isolated from various animals. Can. Vet. J. 2011, 52, 153–157. [Google Scholar] [PubMed]
  32. Atshan, S.S.; Nor Shamsudin, M.; Lung, L.T.; Sekawi, Z.; Pei Pei, C.; Karunanidhi, A.; Jeevajothi Nathan, J.; Mateg Ali, A.; Ghaznavi-Rad, E.; Abduljaleel, S.A.; et al. Genotypically different clones of Staphylococcus aureus are diverse in the antimicrobial susceptibility patterns and biofilm formations. Biomed Res. Int. 2013, 2013, 515712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Bondock, S.; Rabie, R.; Etman, H.A.; Fadda, A.A. Synthesis and antimicrobial activity of some new heterocycles incorporating antipyrine moiety. Eur J. Med. Chem. 2008, 43, 2122–2129. [Google Scholar] [CrossRef] [PubMed]
  34. Saravanan, J.; Mohan, S.; Roy, J.J. Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d] [1,2,3]-triazin-4 (3H)-ones as potential antimicrobial agents. Eur J. Med. Chem. 2010, 45, 4365–4369. [Google Scholar] [CrossRef] [PubMed]
  35. El-Gohary, N.S.; Hawas, S.S.; Gabr, M.T.; Shaaban, M.I.; El-Ashmawy, M.B. New series of fused pyrazolopyridines: Synthesis, molecular modeling, antimicrobial, antiquorum-sensing and antitumor activities. Bioorganic Chem. 2019, 92, 103109. [Google Scholar] [CrossRef] [PubMed]
  36. Liu, H.; Long, S.; Rakesh, K.P.; Zha, G.F. Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents. Eur. J. Med. Chem. 2019, 23, 111804. [Google Scholar] [CrossRef] [PubMed]
  37. Gebreyohannes, G.; Nyerere, A.; Bii, C.; Sbhatu, D.B. Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms. Heliyon 2019, 5, e02192. [Google Scholar] [CrossRef] [Green Version]
  38. Sheldrick, G. A short history of SHELX. Acta Crystallogr. Sect. A Found. Crystallogr. 2008, 64, 112–122. [Google Scholar] [CrossRef] [Green Version]
  39. Armarego, W.L.F.; Chai, C. Purification of Laboratory Chemicals, 5th ed.; Elsevier: Oxford, UK, 2003. [Google Scholar]
  40. Hargreaves, T.; Eyles, H.G.; Peters, A.T. New intermediates and dyes. Part XI. Novel nucleophilic substitution and group elimination in the 2-carbamoylanthraquinone series. J. Chem. Soc. C Org. 1968, 19, 2431–2435. [Google Scholar] [CrossRef]
  41. Samoilova, A.A.; Gladkova, V.V. Compatibility of bicomponent mixtures of disperse dyes. Tekstil’naya Promyshlennost 1981, 8, 57–59. [Google Scholar]
  42. Clinical Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement; CLSI document M100–S17; CLSI: Wayne, PA, USA, 2007. [Google Scholar]
  43. Rex, J.H. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition; Clinical & Laboratory Standards Institute: Wayne, PA, USA, 2008; CLSI Document M27-A3. [Google Scholar]
  44. Walencka, E.; Sadowska, B.; Rozalska, S.; Hryniewicz, W.; Rozalska, B. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol. J. Microbiol. 2005, 54, 191–200. [Google Scholar] [PubMed]
  45. Kairo, S.K.; Bedwell, J.; Tyler, P.C.; Carter, A.; Corbel, M.J. Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines. Vaccine 1999, 17, 2423–2428. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds 5–38 are available from the authors.
Molecules 24 04581 sch001 550
Scheme 1. Synthesis of amides 5–21. Reagents and conditions: (i) thionyl chloride (3 eguiv), pyridine (0.15 equiv), dry benzene, 80 °C, 5 h, (ii) for compounds 5 and 14—25% NH4OH (50 mL), −15 °C, 1 h → 80 °C, 3 h → r.t., 10% HCl; for compounds 6–13, 15–21—R1NH2 (1.1 equiv), dry benzene, TEA (1.1 equiv), ∆, 12 h.
Scheme 1. Synthesis of amides 5–21. Reagents and conditions: (i) thionyl chloride (3 eguiv), pyridine (0.15 equiv), dry benzene, 80 °C, 5 h, (ii) for compounds 5 and 14—25% NH4OH (50 mL), −15 °C, 1 h → 80 °C, 3 h → r.t., 10% HCl; for compounds 6–13, 15–21—R1NH2 (1.1 equiv), dry benzene, TEA (1.1 equiv), ∆, 12 h.
Molecules 24 04581 sch001
Molecules 24 04581 sch002 550
Scheme 2. Synthesis of anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38.
Scheme 2. Synthesis of anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones 22–38.
Molecules 24 04581 sch002
Molecules 24 04581 g001 550
Figure 1. Molecular structure of 22. Ellipsoids are drawn at 50% probability level (CCDC 1966785).
Figure 1. Molecular structure of 22. Ellipsoids are drawn at 50% probability level (CCDC 1966785).
Molecules 24 04581 g001
Molecules 24 04581 g002 550
Figure 2. Molecular packing of 22 (viewed along the a crystallographic axis).
Figure 2. Molecular packing of 22 (viewed along the a crystallographic axis).
Molecules 24 04581 g002
Molecules 24 04581 g003a 550Molecules 24 04581 g003b 550
Figure 3. Results of the kinetic time—kill assay for compounds 32–34 and 36.
Figure 3. Results of the kinetic time—kill assay for compounds 32–34 and 36.
Molecules 24 04581 g003aMolecules 24 04581 g003b
Table
Table 1. Parameters of hydrogen bonds in crystal of compound 22.
Table 1. Parameters of hydrogen bonds in crystal of compound 22.
D-H ···AD-H(Å)D···A(Å)D-H-A(°)
N3-H3···O41.01(3)2.732(3)175 (3)
O4-H41··· O1_$1 *0.92(5)2.844(3)166 (4)
O4-H42 ···O2_$2 *0.91(5)2.867(4)142 (3)
O4-H42 ···N1_$2 *0.91(5)3.097(3)143 (3)
* The atoms marked by symbol $1 and $2 are connected to base atoms by symmetry operations 1 − x, 3 − y, −z and 1 − x, y + 0.5, −z − 0.5, respectively.
Table
Table 2. Antimicrobial activity (MIC, μg/mL) of synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones and randomly selected antibiotics.
Table 2. Antimicrobial activity (MIC, μg/mL) of synthesized anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones and randomly selected antibiotics.
AgentPathogen
S. aureus ATCC 25923S. aureus ATCC 29213S. epidermidis ATCC 12228E. coli ATCC 25922P. aeruginosa ATCC 27853C. albicans ATCC 10231C. albicans SC 5314C. glabrata DSM11226C. krusei DSM6128
224.04.08.0>32.0>32.0>32.0>32.0>32.0>32.0
232.02.01.0>32.0>32.0>32.0>32.0>32.0>32.0
240.50.50.5>32.0>32.0>32.0>32.0>32.032.0
254.08.08.0>32.0>32.0>32.0>32.0>32.0>32.0
262.04.02.0>32.0>32.0>32.0>32.0>32.0>32.0
274.08.08.0>32.0>32.0>32.0>32.0>32.0>32.0
281.02.02.0>32.0>32.0>32.0>32.0>32.0>32.0
292.016.02.0>32.0>32.0>32.0>32.0>32.0>32.0
302.02.02.0>32.0>32.0>32.0>32.0>32.0>32.0
318.04.08.0>32.0>32.0>32.0>32.0>32.0>32.0
320.250.250.125>32.0>32.0>32.0>32.0>32.0>32.0
330.250.250.25>32.0>32.0>32.0>32.0>32.0>32.0
340.250.50.25>32.0>32.0>32.0>32.0>32.0>32.0
354.08.08.0>32.0>32.0>32.0>32.0>32.0>32.0
360.250.50.125>32.0>32.0>32.0>32.0>32.0>32.0
370.51.00.125>32.0>32.0>32.0>32.0>32.0>32.0
381.02.02.0>32.0>32.0>32.0>32.0>32.032.0
Ampicillin0.258.016>32.0>32.0NDNDNDND
Gentamicin0.1250.50.52.02.0NDNDNDND
Fusidic acid0.50.250.125>32.0>32.0NDNDNDND
Linezolid2.01.01.0>32.0>32.0NDNDNDND
Daptomycin1.01.02.0>32.0>32.0NDNDNDND
Oxacillin0.250.1250.125>32.0>32.0NDNDNDND
Levofloxacin0.1250.250.125>32.0>32.0NDNDNDND
Eight substances selected for investigation of their activity against clinical isolates are marked with a gray background and four compounds with the highest activity that were selected for further study (kill-time assay, antibiofilm activity, and influence on enzyme activity) are underlined and bolded. ND—not determined.
Table
Table 3. Antimicrobial activity (MIC, μg/mL) of eight selected compounds against clinical isolates of S. aureus (MSSA and MRSA).
Table 3. Antimicrobial activity (MIC, μg/mL) of eight selected compounds against clinical isolates of S. aureus (MSSA and MRSA).
AgentPathogens—Clinical Isolates of S. aureus
12345678MRSA1MRSA2MRSA3MRSA4
234.08.04.08.08.08.08.08.08.02.08.08.0
241.01.00.50.250.251.00.50.51.01.00.50.5
262.02.01.01.01.04.01.02.04.02.01.02.0
320.250.250.250.250.250.50.250.1250.250.250.250.25
330.50.50.50.50.50.50.50.50.50.50.250.5
340.250.50.250.250.50.250.250.250.50.1250.250.25
360.250.50.250.51.00.50.250.50.51.00.250.5
370.50.50.51.01.00.51.00.51.01.01.02.0
Table
Table 4. Influence of selected compounds on enzymatic activity of S. aureus ATCC 29,213.
Table 4. Influence of selected compounds on enzymatic activity of S. aureus ATCC 29,213.
CompoundEnzyme
Alkaline PhosphataseEsterase (C4)Esterase Lipase (C8)Acid PhosphataseNaphthol-AS-BI-Phosphohydrolase
Control55555
3245455
3334455
3433455
3642455
Table
Table 5. MSSA and MRSA strains used for investigation of antistaphylococcal potential of synthesized agents.
Table 5. MSSA and MRSA strains used for investigation of antistaphylococcal potential of synthesized agents.
No.Code of the StrainMaterialWard of HospitalAntibiogram—Susceptibility Profile 1
14471313Nasal swabIntensive carePen.—R, Met.—S, Clin.—S, Ery.—S
24475564Nasal swabInternalPen.—R, Met.—S, Clin.—R, Ery.—R
34476206SputumInternalPen.—R, Met.—S, Clin.—R, Ery.—R
44475131PusInternalPen.—R, Met.—S, Clin.– R, Ery.—R
54466686SputumSurgicalPen.—R, Met.—S, Clin.—R, Ery.—R
64466380WoundSurgicalPen.—R, Met.—S, Clin.—S, Ery.—S
74466896Nasal swabInternalPen.—R, Met.—S, Clin.—S, Ery.—S
84468792Pharyngeal swabPediatricsPen.—R, Met.—S, Clin.—S, Ery.—S
9-MRSA9572250WoundInternalPen.—R, Met.—R, Clin.—R, Ery.—R
10-MRSA8007171WoundLaryngologyPen.—R, Met.—R, Clin.—R, Ery.—R
11-MRSA45300223BloodPediatricsPen.—R, Met—R, Clin.—R, Ery.—R
12-MRSA9935169WoundDispensaryPen.—R, Met.—R, Clin.—R, Ery.—R
1 Identification of bacterial isolates and antibiograms were performed by Laboratory of Clinical Microbiology, University Centre for Laboratory Diagnostics, Medical University of Gdańsk Clinical Centre with Vitek2 Biomerieux system; Pen—Penicillin, Met—Methicillin, Clin—Clindamycin, Ery—Erythromycin, R—resistant, S—sensitive.

Share and Cite

MDPI and ACS Style

Zvarych, V.; Stasevych, M.; Novikov, V.; Rusanov, E.; Vovk, M.; Szweda, P.; Grecka, K.; Milewski, S. Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a New Class of Antistaphylococcal Agents: Synthesis and Biological Evaluation. Molecules 2019, 24, 4581. https://doi.org/10.3390/molecules24244581

AMA Style

Zvarych V, Stasevych M, Novikov V, Rusanov E, Vovk M, Szweda P, Grecka K, Milewski S. Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a New Class of Antistaphylococcal Agents: Synthesis and Biological Evaluation. Molecules. 2019; 24(24):4581. https://doi.org/10.3390/molecules24244581

Chicago/Turabian Style

Zvarych, Viktor, Maryna Stasevych, Volodymyr Novikov, Eduard Rusanov, Mykhailo Vovk, Piotr Szweda, Katarzyna Grecka, and Slawomir Milewski. 2019. "Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a New Class of Antistaphylococcal Agents: Synthesis and Biological Evaluation" Molecules 24, no. 24: 4581. https://doi.org/10.3390/molecules24244581

Article Metrics

Back to TopTop